Elizabeth Buck

Summary

Affiliation: OSI Pharmaceuticals
Country: USA

Publications

  1. ncbi request reprint Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition
    Stuart Thomson
    Departments of Translational Research and Oncology Research, OSI Pharmaceuticals, Inc, Farmingdale, NY 11735, USA
    Cancer Res 65:9455-62. 2005
  2. ncbi request reprint Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity
    Elizabeth Buck
    Department of Translational Research, OSI Pharmaceuticals, Inc, 1 Bioscience Park Drive, Farmingdale, NY 11787, USA
    Mol Cancer Ther 5:2051-9. 2006
  3. doi request reprint Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors
    Elizabeth Buck
    Translational Research, Cancer Biology, OSI Pharmaceuticals, Farmingdale, New York 11735, USA
    Cancer Res 68:8322-32. 2008
  4. ncbi request reprint Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors
    Elizabeth Buck
    OSI Pharmaceuticals, 1 Bioscience Park Drive, Farmingdale, NY 11787, USA
    Mol Cancer Ther 5:2676-84. 2006
  5. doi request reprint Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer
    Elizabeth Buck
    Translational Research, OSI Pharmaceuticals, Farmingdale, NY 11735, USA
    Expert Opin Investig Drugs 20:605-21. 2011
  6. doi request reprint Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer
    Elizabeth Buck
    Translational Research, OSI Pharmaceuticals, Inc, Farmingdale, New York 11735, USA
    Mol Cancer Ther 9:2652-64. 2010
  7. doi request reprint Pursuit of personalized anticancer therapy: leveraging collaboration between academia and the biotech/pharmaceutical industry
    Elizabeth Buck
    OSI Pharmaceuticals, Farmingdale, NY, USA
    Mt Sinai J Med 77:358-65. 2010
  8. ncbi request reprint Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
    Elizabeth Buck
    OSI Pharmaceuticals, Inc, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA
    Mol Cancer Ther 6:532-41. 2007
  9. ncbi request reprint A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo
    Qun sheng Ji
    Oncology, OSI Pharmaceuticals, Inc, New York, New York, USA
    Mol Cancer Ther 6:2158-67. 2007
  10. doi request reprint Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor
    Mark J Mulvihill
    OSI Oncology, OSI Pharmaceuticals, Inc, 41 Pinelawn, Melville, NY 11747, USA
    Future Med Chem 1:1153-71. 2009

Detail Information

Publications13

  1. ncbi request reprint Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition
    Stuart Thomson
    Departments of Translational Research and Oncology Research, OSI Pharmaceuticals, Inc, Farmingdale, NY 11735, USA
    Cancer Res 65:9455-62. 2005
    ..These data suggest that EMT may be a general biological switch rendering non-small cell lung tumors sensitive or insensitive to EGFR inhibition...
  2. ncbi request reprint Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity
    Elizabeth Buck
    Department of Translational Research, OSI Pharmaceuticals, Inc, 1 Bioscience Park Drive, Farmingdale, NY 11787, USA
    Mol Cancer Ther 5:2051-9. 2006
    ..These studies suggest that HER-3 could be used as a biomarker to select patients who are most likely to respond to erlotinib therapy...
  3. doi request reprint Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors
    Elizabeth Buck
    Translational Research, Cancer Biology, OSI Pharmaceuticals, Farmingdale, New York 11735, USA
    Cancer Res 68:8322-32. 2008
    ..Collectively, these data show that resistance to inhibition of MEK, mTOR, and EGFR is associated with enhanced IGF-IR-directed Akt signaling, where all affect feedback loops converging at the level of IRS-1...
  4. ncbi request reprint Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors
    Elizabeth Buck
    OSI Pharmaceuticals, 1 Bioscience Park Drive, Farmingdale, NY 11787, USA
    Mol Cancer Ther 5:2676-84. 2006
    ..These results suggest that combining rapamycin with erlotinib might be clinically useful to enhance response to erlotinib...
  5. doi request reprint Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer
    Elizabeth Buck
    Translational Research, OSI Pharmaceuticals, Farmingdale, NY 11735, USA
    Expert Opin Investig Drugs 20:605-21. 2011
    ..Currently, both IGF-1R-neutralizing antibodies and small-molecule tyrosine kinase inhibitors of IGF-1R/IR are in clinical development...
  6. doi request reprint Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer
    Elizabeth Buck
    Translational Research, OSI Pharmaceuticals, Inc, Farmingdale, New York 11735, USA
    Mol Cancer Ther 9:2652-64. 2010
    ..Collectively, these data indicate that cotargeting IGF-1R and IR may provide superior antitumor efficacy compared with targeting IGF-1R alone...
  7. doi request reprint Pursuit of personalized anticancer therapy: leveraging collaboration between academia and the biotech/pharmaceutical industry
    Elizabeth Buck
    OSI Pharmaceuticals, Farmingdale, NY, USA
    Mt Sinai J Med 77:358-65. 2010
    ....
  8. ncbi request reprint Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
    Elizabeth Buck
    OSI Pharmaceuticals, Inc, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA
    Mol Cancer Ther 6:532-41. 2007
    ....
  9. ncbi request reprint A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo
    Qun sheng Ji
    Oncology, OSI Pharmaceuticals, Inc, New York, New York, USA
    Mol Cancer Ther 6:2158-67. 2007
    ..Thus, PQIP represents a potent and selective IGF-IR kinase inhibitor that is especially efficacious in an IGF-II-driven human tumor model...
  10. doi request reprint Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor
    Mark J Mulvihill
    OSI Oncology, OSI Pharmaceuticals, Inc, 41 Pinelawn, Melville, NY 11747, USA
    Future Med Chem 1:1153-71. 2009
    ..The IGF-1 receptor (IGF-1R) has been implicated in the promotion of tumorigenesis, metastasis and resistance to cancer therapies. Therefore, this receptor has become a major focus for the development of anticancer agents...
  11. pmc Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions
    Sharon Barr
    OSI Pharmaceuticals Inc, 1 Bioscience Park Dr, Farmingdale, NY 11735, USA
    Clin Exp Metastasis 25:685-93. 2008
    ..The interaction between EGFR and the multiple signaling nodes which regulate EMT suggest that the combination of an EGFR inhibitor and other molecular targeted agents may offer a novel approach to controlling metastasis...
  12. doi request reprint Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines
    Hui Zhao
    Department of Translational Research, OSI Pharmaceuticals, Inc, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA
    Mol Cancer Ther 11:503-13. 2012
    ....
  13. doi request reprint Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution
    Meizhong Jin
    OSI Pharmaceuticals LLC, Farmingdale, NY 11735, USA
    Future Med Chem 4:315-28. 2012
    ..This is an important area to be discussed since one of the major challenges in kinase inhibitor drug discovery is to build an optimal selectivity profile based on biological rationale...